Get the Daily Brief
Latest Biotech News
Strand Therapeutics raises $153 million for programmable mRNA cancer therapies
Strand Therapeutics, an MIT spinout developing programmable mRNA-based immunotherapies for solid tumors, secured $153 million in a Series B fundraising round led by prominent investors including...
Eli Lilly’s oral GLP-1 obesity pill delivers modest weight loss in Phase 3 data
Eli Lilly disclosed Phase 3 results for orforglipron, an oral small molecule GLP-1 receptor agonist for obesity, showing a 12.4% mean weight loss over 72 weeks at the highest dose, falling short...
Adaptive Biotechnologies posts 36% revenue growth fueled by minimal residual disease testing
Adaptive Biotechnologies reported Q2 2025 revenues of $58.9 million, marking a 36% increase year over year, mainly driven by robust demand for its clinical and pharmaceutical minimal residual...
10x Genomics acquires Scale Biosciences to enhance single-cell biology platform
10x Genomics announced a definitive agreement to acquire single-cell biology company Scale Biosciences for $30 million upfront plus milestone-based contingent payments. Scale’s technologies,...
Merck’s $10 billion acquisition of Verona Pharma reveals no competing bids
Merck finalized a $10 billion acquisition of Verona Pharma, the maker of the newly FDA-approved COPD drug ensifentrine, amidst an atypical absence of competing offers. Documentation revealed Merck...
FDA grants accelerated approval to Jazz Pharmaceuticals’ Modeyso for rare brain cancer
The FDA granted accelerated approval to dordaviprone (Modeyso), developed by Jazz Pharmaceuticals following its acquisition of Chimerix, as the first systemic therapy for recurrent H3 K27M-mutant...
Bio-Techne reports 4% fiscal Q4 revenue growth amid macroeconomic uncertainty
Bio-Techne announced fiscal Q4 2025 revenues of $317 million, a 4% year-over-year increase, driven by strong performance in protein sciences and cell therapy workflow consumables despite a slight...
Scientists reveal lithium deficiency’s role in Alzheimer’s pathology and reversal strategy
Harvard Medical School researchers identified brain lithium deficiency as an early and pivotal factor in Alzheimer’s disease onset and progression. Through mouse models and human tissue studies,...
Frazier Life Sciences Raises $1.3 Billion for Early-Stage Biopharma
Frazier Life Sciences closed its twelfth venture fund, FLS XII, securing $1.3 billion in capital commitments to invest in company creation and early-stage private biopharmaceutical firms. Since...
US Health Agencies Cancel $500M in mRNA Vaccine Funding
The US Department of Health and Human Services (HHS) announced the cancellation of nearly $500 million in contracts for 22 mRNA vaccine development projects under the Biomedical Advanced Research...
Strand Therapeutics Raises $153 Million to Advance Programmable mRNA Cancer Drugs
Strand Therapeutics has secured $153 million in a Series B financing round led by global investors including Kinnevik, Regeneron Ventures, Amgen Ventures, and Eli Lilly. The funding will support...
Eli Lilly’s Oral GLP-1 Obesity Drug Shows Modest Weight Loss Benefits
Eli Lilly disclosed results from a pivotal Phase 3 trial of its oral GLP-1 receptor agonist, orforglipron, reporting an average placebo-adjusted weight loss of 11.2% over 72 weeks in adults with...
10x Genomics Acquires Scale Biosciences to Expand Single-Cell Platform
10x Genomics announced an acquisition of Scale Biosciences for $30 million upfront plus milestone payments, aiming to enhance its Chromium single-cell biology platform with Scale’s split-pool...
Adaptive Biotechnologies Reports Strong Q2 on MRD Testing Growth
Adaptive Biotechnologies posted a 36% year-over-year revenue increase to $58.9 million for the second quarter driven primarily by its minimal residual disease (MRD) testing business. Revenues from...
Jazz Pharmaceuticals Gains FDA Approval for Rare Pediatric Brain Cancer Drug
Jazz Pharmaceuticals secured accelerated FDA approval for dordaviprone (Modeyso), the first systemic treatment for recurrent H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain...
Merck Acquires Verona Pharma in $10 Billion Deal Without Competition
Merck closed its $10 billion acquisition of Verona Pharma, a transaction uncontested by other bidders despite Verona’s recent FDA approval of OhtuvayreTM, a novel nebulized treatment for chronic...
Deep Learning and AI Fuel Medical Imaging and Diagnostic Innovations
Recent studies highlight the rapid integration of deep learning and artificial intelligence across medical imaging and diagnostics. Advances include enhanced cranial ultrasound methods for brain...
HHS Ends mRNA Vaccine Development: Impact on Future Biotech
The U.S. Department of Health and Human Services (HHS) has announced the termination of 22 contracts, canceling nearly $500 million in funding for mRNA vaccine development at the Biomedical...
Strand Therapeutics Raises $153M for Programmable mRNA Cancer Drugs
Strand Therapeutics, an MIT spinout pioneering programmable messenger RNA-based therapies aimed at solid tumors, has secured $153 million in Series B funding. The capital will accelerate clinical...
Eli Lilly’s Oral GLP-1 Obesity Pill Shows Modest Weight Loss in Phase 3
Eli Lilly has reported results from a pivotal Phase 3 trial of orforglipron, an oral GLP-1 receptor agonist for obesity, demonstrating an average weight loss of 11.2% at 72 weeks for the highest...